Sarepta Therapeutics Shares Early siRNA Data in FSHD and DM1 Trials, Highlights Biomarker Knockdown

Sarepta Therapeutics (NASDAQ:SRPT) presented preliminary clinical data from ongoing phase I/II studies of two investigational ...

Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript

Good morning, and welcome to Sarepta's preliminary data readout of its Phase I/II studies for DM1 and FSHD. As a reminder, today's program is being recorded. At this time, I'll turn the call over to ...